CN101810593A - 一种榄香烯缓释片 - Google Patents
一种榄香烯缓释片 Download PDFInfo
- Publication number
- CN101810593A CN101810593A CN201010165908A CN201010165908A CN101810593A CN 101810593 A CN101810593 A CN 101810593A CN 201010165908 A CN201010165908 A CN 201010165908A CN 201010165908 A CN201010165908 A CN 201010165908A CN 101810593 A CN101810593 A CN 101810593A
- Authority
- CN
- China
- Prior art keywords
- elemene
- sustained
- release tablets
- microcrystalline cellulose
- filler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 title claims abstract description 104
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 title claims abstract description 95
- 239000007939 sustained release tablet Substances 0.000 title claims abstract description 30
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 29
- 239000000945 filler Substances 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 11
- 239000000314 lubricant Substances 0.000 claims abstract description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 36
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 36
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 36
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 36
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 27
- 239000008101 lactose Substances 0.000 claims description 27
- 230000003578 releasing effect Effects 0.000 claims description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 22
- 229920002472 Starch Polymers 0.000 claims description 22
- 239000000741 silica gel Substances 0.000 claims description 22
- 229910002027 silica gel Inorganic materials 0.000 claims description 22
- 239000011734 sodium Substances 0.000 claims description 21
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 20
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 20
- 229910052708 sodium Inorganic materials 0.000 claims description 20
- 239000008107 starch Substances 0.000 claims description 20
- 235000019698 starch Nutrition 0.000 claims description 20
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 19
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 19
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 13
- 229920000609 methyl cellulose Polymers 0.000 claims description 12
- 239000001923 methylcellulose Substances 0.000 claims description 12
- 235000010981 methylcellulose Nutrition 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 10
- 206010013786 Dry skin Diseases 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 7
- 239000001856 Ethyl cellulose Substances 0.000 claims description 7
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 7
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 7
- 229920001249 ethyl cellulose Polymers 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- MXDMETWAEGIFOE-CABCVRRESA-N delta-elemene Chemical compound CC(C)C1=C[C@H](C(C)=C)[C@@](C)(C=C)CC1 MXDMETWAEGIFOE-CABCVRRESA-N 0.000 claims description 6
- RVOXATXFYDNXRE-UHFFFAOYSA-N gamma-elemene Natural products CC(=C1CCC(C)(C(C1)C(=C)C)C(=C)C)C RVOXATXFYDNXRE-UHFFFAOYSA-N 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- QDUJKDRUFBJYSQ-UHFFFAOYSA-N alpha-elemene Natural products CC(C)C1=CC(=C(C)C)CCC1(C)C=C QDUJKDRUFBJYSQ-UHFFFAOYSA-N 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- BQSLMQNYHVFRDT-CABCVRRESA-N (-)-gamma-Elemene Natural products CC(C)=C1CC[C@](C)(C=C)[C@@H](C(C)=C)C1 BQSLMQNYHVFRDT-CABCVRRESA-N 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- BQSLMQNYHVFRDT-LSDHHAIUSA-N gamma-elemene Chemical compound CC(C)=C1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 BQSLMQNYHVFRDT-LSDHHAIUSA-N 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- MXDMETWAEGIFOE-UHFFFAOYSA-N rac-delta-elemene Natural products CC(C)C1=CC(C(C)=C)C(C)(C=C)CC1 MXDMETWAEGIFOE-UHFFFAOYSA-N 0.000 claims description 3
- 235000019890 Amylum Nutrition 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 239000003826 tablet Substances 0.000 abstract description 4
- 238000013268 sustained release Methods 0.000 abstract description 3
- 239000012730 sustained-release form Substances 0.000 abstract description 3
- 239000003405 delayed action preparation Substances 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 230000003203 everyday effect Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 229960003943 hypromellose Drugs 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 239000003005 anticarcinogenic agent Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000005619 esophageal carcinoma Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- -1 1-methyl isophthalic acid-vinyl-2,4-diisopropenyl cyclohexane Chemical compound 0.000 description 1
- JBDYKGMNMDIHFL-UHFFFAOYSA-N 1-nitroanthracene Chemical class C1=CC=C2C=C3C([N+](=O)[O-])=CC=CC3=CC2=C1 JBDYKGMNMDIHFL-UHFFFAOYSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241001547405 Chloranthus multistachys Species 0.000 description 1
- 241000721156 Chloranthus spicatus Species 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 231100000777 Toxicophore Toxicity 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- QDUJKDRUFBJYSQ-OAHLLOKOSA-N elemene Chemical compound CC(C)C1=CC(=C(C)C)CC[C@@]1(C)C=C QDUJKDRUFBJYSQ-OAHLLOKOSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
组分 | 微晶纤维素 | 乳糖 | 羧甲基淀粉钠 | 羟丙甲纤维素K-15M | 微粉硅胶 | 8%淀粉水溶液 | β-榄香烯 |
用量/g | 25 | 10 | 2 | 2 | 4 | 3 | 6 |
组分 | 微晶纤维素 | 乳糖 | 羧甲基淀粉钠 | 羟丙甲纤维素K-15M | 微粉硅胶 | 8%淀粉水溶液 | β-榄香烯 |
用量/g | 25 | 10 | 2 | 4.25 | 4.2 | 4 | 6 |
组分 | 微晶纤维素 | 乳糖 | 羧甲基淀粉钠 | 甲基纤维素 | 微粉硅胶 | 8%淀粉水溶液 | β-榄香烯 |
用量/g | 25 | 10 | 2 | 2 | 4 | 3 | 6 |
组分 | 微晶纤维素 | 乳糖 | 羧甲基淀粉钠 | 甲基纤维素 | 微粉硅胶 | 8%淀粉水溶液 | β-榄香烯 |
用量/g | 25 | 10 | 2 | 4.25 | 4 | 4 | 6 |
组分 | 微晶纤维素 | 羧甲基淀粉钠 | 羟丙甲纤维素K-15M | 微粉硅胶 | 8%淀粉水溶液 | β-榄香烯 |
用量/g | 35 | 3.25 | 2 | 4 | 3 | 6 |
组分 | 微晶纤维素 | 羧甲基淀粉钠 | 羟丙甲纤维素K-15M | 微粉硅胶 | 8%淀粉水溶液 | β-榄香烯 |
用量/g | 35 | 3.25 | 4.25 | 4 | 4 | 6 |
组分 | 微晶纤维素 | β-环糊精 | 乳糖 | 羧甲基淀粉钠 | 羟丙甲纤维素K-15M | 微粉硅胶 | 8%淀粉水溶液 | β-榄香烯 |
用量/g | 27.5 | 10 | 15 | 3 | 6.4 | 6 | 6 | 9 |
Claims (10)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010165908XA CN101810593B (zh) | 2010-05-10 | 2010-05-10 | 一种榄香烯缓释片 |
US13/697,138 US8778417B2 (en) | 2010-05-10 | 2011-04-08 | Anti-tumor plant-medicament sustained-release tablet of elemene |
PCT/CN2011/072530 WO2011140872A1 (zh) | 2010-05-10 | 2011-04-08 | 抗肿瘤植物药榄香烯缓释片 |
EP11780093.8A EP2570121B1 (en) | 2010-05-10 | 2011-04-08 | Slow release tablet of elemene anti-tumor plant medicine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010165908XA CN101810593B (zh) | 2010-05-10 | 2010-05-10 | 一种榄香烯缓释片 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101810593A true CN101810593A (zh) | 2010-08-25 |
CN101810593B CN101810593B (zh) | 2012-07-18 |
Family
ID=42618056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010165908XA Active CN101810593B (zh) | 2010-05-10 | 2010-05-10 | 一种榄香烯缓释片 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8778417B2 (zh) |
EP (1) | EP2570121B1 (zh) |
CN (1) | CN101810593B (zh) |
WO (1) | WO2011140872A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114521557A (zh) * | 2021-12-21 | 2022-05-24 | 上海交通大学重庆研究院 | 一种驱鸟缓释剂及其制备方法与应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014078435A1 (en) | 2012-11-14 | 2014-05-22 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
CN109789095A (zh) * | 2016-07-25 | 2019-05-21 | Ebbu 公司 | 新的大麻片剂配方和组合物及其制造方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1508176A (zh) * | 2002-12-18 | 2004-06-30 | 沈阳市万嘉生物技术研究所 | 榄香烯的羟丙基-β-环糊精包合物及其制剂和制备方法 |
CN1990047A (zh) * | 2005-12-29 | 2007-07-04 | 刘玉辉 | 一种榄香烯包合物、其制剂及制备方法 |
WO2008036932A2 (en) * | 2006-09-21 | 2008-03-27 | Herbalscience Singapore Pte. Ltd. | Compositions and methods comprising boswellia species |
CN101402543A (zh) * | 2008-11-14 | 2009-04-08 | 沈阳万爱普利德医药科技有限公司 | 一种β-榄香烯原料药及其制剂的制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1060038C (zh) | 1993-02-15 | 2001-01-03 | 大连市医药科学研究所 | 榄香烯乳注射液及其制备方法 |
CN1084187C (zh) | 1997-04-14 | 2002-05-08 | 中国远大国际集团有限公司 | 以β-榄香烯为有效成分的抗癌药物的制备方法及其组成 |
CN1080115C (zh) | 1998-08-12 | 2002-03-06 | 大连科宇药业科技开发有限公司 | 榄香烯注射液及其制备方法 |
CN1221607A (zh) | 1998-11-20 | 1999-07-07 | 大连市医药科学研究所 | 脂溶性药物脂质体生产工艺及榄香烯脂质体注射液 |
CN101306181B (zh) | 2002-04-17 | 2011-06-29 | 谢恬 | 榄香烯脂肪乳注射剂及其制备方法 |
CN100374106C (zh) * | 2002-09-18 | 2008-03-12 | 中国远大国际集团有限公司 | 高纯度榄香烯抗癌药物的制备方法 |
CN1241555C (zh) | 2002-12-18 | 2006-02-15 | 上海医药工业研究院 | 榄香烯脂肪乳注射液及制备方法 |
CN1726906A (zh) * | 2004-07-27 | 2006-02-01 | 辽宁卫星制药厂(有限责任公司) | 草酸萘呋胺酯缓释片及其生产方法 |
CN1300071C (zh) | 2004-11-30 | 2007-02-14 | 河北科技大学 | 超临界co2流体萃取-精馏提取莪术中榄香烯的方法 |
CN1303046C (zh) | 2005-04-17 | 2007-03-07 | 仇德安 | 从温郁金中提取β-榄香烯抗癌原料药物的生产工艺 |
CN101125124B (zh) * | 2006-08-16 | 2011-04-20 | 沈阳药科大学 | 一种亲脂性药物固体分散体的制备方法 |
CN101461793B (zh) | 2009-01-09 | 2012-06-20 | 四川省中医药科学院 | β-榄香烯脂质体及冻干粉的制备方法 |
-
2010
- 2010-05-10 CN CN201010165908XA patent/CN101810593B/zh active Active
-
2011
- 2011-04-08 US US13/697,138 patent/US8778417B2/en active Active
- 2011-04-08 EP EP11780093.8A patent/EP2570121B1/en active Active
- 2011-04-08 WO PCT/CN2011/072530 patent/WO2011140872A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1508176A (zh) * | 2002-12-18 | 2004-06-30 | 沈阳市万嘉生物技术研究所 | 榄香烯的羟丙基-β-环糊精包合物及其制剂和制备方法 |
CN1990047A (zh) * | 2005-12-29 | 2007-07-04 | 刘玉辉 | 一种榄香烯包合物、其制剂及制备方法 |
WO2008036932A2 (en) * | 2006-09-21 | 2008-03-27 | Herbalscience Singapore Pte. Ltd. | Compositions and methods comprising boswellia species |
CN101402543A (zh) * | 2008-11-14 | 2009-04-08 | 沈阳万爱普利德医药科技有限公司 | 一种β-榄香烯原料药及其制剂的制备方法 |
Non-Patent Citations (2)
Title |
---|
《肿瘤防治研究》 19961005 钱军等 《榄香烯乳逆转入肺癌细胞的实验研究》 第299-301页 1-10 第23卷, 第5期 2 * |
《辽宁中医药大学学报》 20080305 洪滨 《榄香烯注射液治疗恶性脑转移瘤18例》 第71-72页 1-10 第10卷, 第3期 2 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114521557A (zh) * | 2021-12-21 | 2022-05-24 | 上海交通大学重庆研究院 | 一种驱鸟缓释剂及其制备方法与应用 |
CN114521557B (zh) * | 2021-12-21 | 2023-11-24 | 上海交通大学重庆研究院 | 一种驱鸟缓释剂及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
US20130059922A1 (en) | 2013-03-07 |
EP2570121A1 (en) | 2013-03-20 |
CN101810593B (zh) | 2012-07-18 |
EP2570121B1 (en) | 2015-10-14 |
US8778417B2 (en) | 2014-07-15 |
EP2570121A4 (en) | 2014-06-25 |
WO2011140872A1 (zh) | 2011-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101810593B (zh) | 一种榄香烯缓释片 | |
CN1706397B (zh) | 具有升高白细胞作用的芍药苷与芍药内酯苷的组合物 | |
CN102085344B (zh) | 一种木香顺气缓释制剂及其制备方法 | |
US20080274215A1 (en) | Composition for treatment of cold and flu | |
CN104771400A (zh) | 一种双乙酰大黄酸和小檗碱的口服药物组合物及其应用 | |
CN101658507B (zh) | 一种愈创木酚甘油醚和伪麻黄碱的复方缓释制剂 | |
CN104352427A (zh) | 一种含有穿心莲内酯的药物组合物及其用途 | |
CN103211999B (zh) | 一种治疗急慢性肝炎的缓释微丸及其制备方法和应用 | |
CN101543481B (zh) | 一种双层灯盏花素缓释片及制备方法 | |
CN103301079A (zh) | 一种卡培他滨药物组合物及其制备方法 | |
CN101244068B (zh) | 雪胆素缓释制剂 | |
CN101518519A (zh) | 一种柚皮苷缓释片及其制备方法 | |
CN101744881B (zh) | 包衣材料和致孔剂的混合物在制备中药组合物方面的应用 | |
CN101780094B (zh) | 雪胆素缓释制剂 | |
CN109718226B (zh) | 抗感缓释微丸及其制备方法 | |
CN101829121B (zh) | 雪胆素缓释制剂 | |
CN1939445B (zh) | 一种枇杷叶水提取物的制备方法与用途 | |
CN101766608B (zh) | 复方盐酸伪麻黄碱缓释制剂及其制备方法 | |
CN105055628A (zh) | 一种治疗性早熟的药物组合物及其应用 | |
CN104771401A (zh) | 一种双乙酰大黄酸和小檗碱的口服药物组合物 | |
CN103315979A (zh) | 一种高乌甲素缓释制剂组合物及其制备方法 | |
CN102397274A (zh) | 岩白菜素在制备治疗糖尿病药物中的用途 | |
CN1981816B (zh) | 一种治疗缺血性心脏病的中药组合物、制剂及其用途 | |
CN1981818B (zh) | 治疗心血管疾病的中药组合物、制剂及其用途 | |
CN103893368B (zh) | 无糖型仙灵地黄组合物及其颗粒剂和制法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: XIE TIAN Free format text: FORMER OWNER: HANGZHOU PHARMSUN PHARMACEUTICAL CO., LTD. Effective date: 20120606 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310012 HANGZHOU, ZHEJIANG PROVINCE TO: 310013 HANGZHOU, ZHEJIANG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20120606 Address after: Hangzhou City, Zhejiang province 310013 Xihu District Qiushi Road No. 36 Luyuan Ginkgo Garden 3-1902 Applicant after: Xie Tian Address before: 606 room 310012, West Lake building, 202 Wen two road, Zhejiang, Hangzhou, China Applicant before: Hangzhou Pharmsun Pharmaceutical Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100825 Assignee: Dalian Holley Kingkong Pharmaceutical Co., Ltd. Assignor: Xie Tian Contract record no.: 2013210000024 Denomination of invention: Elemene sustained-release tablets Granted publication date: 20120718 License type: Exclusive License Record date: 20130329 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 310013, Hangzhou, Zhejiang Province, Tianmu Road, No. 389, leaving the village 4-1-101 Patentee after: Xie Tian Address before: Hangzhou City, Zhejiang province 310013 Xihu District Qiushi Road No. 36 Luyuan Ginkgo Garden 3-1902 Patentee before: Xie Tian |